Home>Topics>Stocks>Given Imaging

Given Imaging GIVN

  1. All
  2. Commentary
    1. Given Imaging Receives FDA Approval for Colonoscopy Product


      Mon, 3 Feb 2014

      On Monday, Given Imaging received long-anticipated domestic regulatory clearance on its PillCam COLON product. We are leaving our fair value estimate

    2. We Like Covidien's Plan to Buy Given Imaging


      Mon, 9 Dec 2013

      With the announcement that wide-moat Covidien will be purchasing narrow-moat Given Imaging , we see Given's long-running search for a buyer coming to a favorable end. We plan to raise our fair value estimate for Given

    3. Given Imaging Prepares for Big New Product Launches in 2014


      Thu, 7 Nov 2013

      Given Imaging posted strong third-quarter results that were largely consistent with our expectations. We are standing behind our $21 per

    4. Given Imaging Posts Strong 2Q, and Prospects Are Bright for 2014


      Wed, 7 Aug 2013

      Given Imaging reported strong second-quarter performance, coming off weak first-quarter results. The firm remains on track to meet our

    5. Given Imaging Posts Mixed Results in 1Q, and We Maintain Our Fair Value Estimate


      Fri, 10 May 2013

      Given Imaging GIVN reported first-quarter results that were a mixed bag, but the adjustments we've made to our assumptions were not material

    6. Given Imaging's Shares Fall After Potential Sale Is Taken Off the Table


      Tue, 15 Jan 2013

      Following the announcement that Given Imaging GIVN is no longer seeking the potential sale of the firm, shares have fallen moderately. However, we are leaving our $18 fair value

    7. Given Imaging Sees Good Signs on Horizon for PillCam COLON


      Wed, 7 Nov 2012

      Given Imaging GIVN reported third-quarter results that were largely consistent with our expectations, and we are standing behind our fair value

    8. Given Imaging Assesses Its Strategic Alternatives


      Thu, 18 Oct 2012

      In an effort to enhance shareholder value, Given Imaging GIVN announced that it was reviewing strategic alternatives to sell itself or merge with another company. The 18% boost to its shares

    9. Currency Drives Givaudan's Reported Sales Growth in First Nine Months; Increasing FVE Modestly


      Tue, 9 Oct 2012

      Givaudan GIVN reported strong interim sales that outpaced our expectations (up 14% in the third quarter), as the impact of favorable foreign

    10. Given Imaging Under Review After Clinical Data Support Limited Indication for PillCam COLON


      Wed, 8 Aug 2012

      We're putting Given Imaging GIVN under review as we reassess our estimates for PillCam COLON in light of the latest clinical data that suggest the product will

    « Prev1234Next »
    Content Partners